Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients

Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(3):135-136. doi: 10.1093/ehjcvp/pvaa028.
No abstract available

Publication types

  • Comment

MeSH terms

  • Aminobutyrates
  • Angiotensin Receptor Antagonists
  • Animals
  • Apolipoproteins
  • Betacoronavirus
  • COVID-19
  • Coronavirus Infections
  • Drug Combinations
  • Humans
  • Inflammation
  • Mice
  • Neprilysin
  • Pandemics
  • Plaque, Atherosclerotic*
  • Pneumonia, Viral
  • SARS Virus*
  • SARS-CoV-2
  • Tetrazoles
  • Valsartan

Substances

  • Aminobutyrates
  • Angiotensin Receptor Antagonists
  • Apolipoproteins
  • Drug Combinations
  • Tetrazoles
  • Valsartan
  • Neprilysin
  • sacubitril and valsartan sodium hydrate drug combination